AVTE vs. ETNB, GOSS, CTMX, IMUX, LPTX, RCKT, CPRX, ZLAB, GLPG, and KROS
Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include 89bio (ETNB), Gossamer Bio (GOSS), CytomX Therapeutics (CTMX), Immunic (IMUX), Leap Therapeutics (LPTX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Zai Lab (ZLAB), Galapagos (GLPG), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical preparations" industry.
89bio (NASDAQ:ETNB) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations.
89bio has a beta of 1.15, indicating that its stock price is 15% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.
Aerovate Therapeutics is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks.
In the previous week, 89bio had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for 89bio and 4 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 1.39 beat 89bio's score of 0.86 indicating that 89bio is being referred to more favorably in the media.
89bio received 81 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. However, 66.67% of users gave Aerovate Therapeutics an outperform vote while only 63.06% of users gave 89bio an outperform vote.
Aerovate Therapeutics' return on equity of -34.76% beat 89bio's return on equity.
89bio currently has a consensus price target of $28.14, suggesting a potential upside of 256.24%. Aerovate Therapeutics has a consensus price target of $47.00, suggesting a potential upside of 169.34%. Given Aerovate Therapeutics' higher probable upside, research analysts plainly believe 89bio is more favorable than Aerovate Therapeutics.
Summary
89bio beats Aerovate Therapeutics on 9 of the 13 factors compared between the two stocks.
Get Aerovate Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aerovate Therapeutics Competitors List
Related Companies and Tools
